Understanding GLP-1 Receptor Agonists: From Single to Triple Agonism

The Incretin System

The incretin system is a gut-hormone signaling axis that plays a central role in glucose homeostasis and energy balance. When food enters the gastrointestinal tract, specialized enteroendocrine cells release incretin hormones that amplify insulin secretion from pancreatic beta cells, a phenomenon known as the “incretin effect.”

In healthy individuals, the incretin effect accounts for 50-70% of the total insulin response to an oral glucose load. This means that the same amount of glucose delivered orally produces a significantly greater insulin response than the same amount delivered intravenously, and incretins are responsible for the difference.

Two hormones dominate the incretin system: GLP-1 and GIP.

The Incretin System: GLP-1 and GIP Signaling

GLP-1 Biology

What Is GLP-1?

Glucagon-like peptide-1 (GLP-1) is a 30-amino acid peptide hormone produced primarily by L-cells in the ileum and colon. It is derived from the proglucagon gene through tissue-specific post-translational processing.

Physiological Actions of GLP-1

• Insulin secretion: Stimulates glucose-dependent insulin release from pancreatic beta cells (only active when blood glucose is elevated, reducing hypoglycemia risk)
• Glucagon suppression: Inhibits glucagon secretion from alpha cells, reducing hepatic glucose output
• Gastric emptying: Slows the rate at which food leaves the stomach, moderating postprandial glucose spikes
• Appetite regulation: Acts on hypothalamic and brainstem receptors to promote satiety and reduce food intake
• Beta cell preservation: Promotes beta cell proliferation and inhibits apoptosis in preclinical models
• Cardiovascular effects: Emerging evidence for cardioprotective properties including reduced inflammation and improved endothelial function

The Half-Life Problem

Native GLP-1 has a plasma half-life of approximately 2 minutes. It is rapidly degraded by the enzyme dipeptidyl peptidase-4 (DPP-4), which cleaves the first two amino acids from the N-terminus, rendering the peptide inactive. This ultrashort half-life makes native GLP-1 impractical as a therapeutic agent, driving the development of resistant analogs.

GIP Biology

What Is GIP?

Glucose-dependent insulinotropic polypeptide (GIP) is a 42-amino acid peptide produced by K-cells in the duodenum and jejunum. It was the first incretin hormone discovered.

Physiological Actions of GIP

• Insulin secretion: Like GLP-1, stimulates glucose-dependent insulin release
• Fat metabolism: Promotes lipid uptake and storage in adipose tissue; also involved in bone metabolism
• Glucagon regulation: Unlike GLP-1, GIP stimulates glucagon secretion during hypoglycemia and suppresses it during hyperglycemia, providing a more nuanced glycemic control
• Central effects: Emerging research suggests GIP receptor signaling in the brain contributes to appetite regulation and nausea reduction

The Glucagon Receptor

Glucagon, produced by pancreatic alpha cells, is classically known for raising blood glucose by stimulating hepatic glycogenolysis and gluconeogenesis. However, glucagon receptor activation also:

• Increases energy expenditure: Stimulates thermogenesis and lipid oxidation
• Reduces appetite: Acts on central nervous system circuits to suppress food intake
• Promotes lipolysis: Mobilizes fat stores for energy utilization
• Increases amino acid catabolism: Drives hepatic amino acid oxidation

These properties make glucagon receptor agonism an attractive addition to incretin-based therapies, particularly for addressing obesity and hepatic steatosis, provided the hyperglycemic effects are counterbalanced by concurrent GLP-1 (and/or GIP) receptor activation.

How GLP-1 Receptor Agonists Work

GLP-1 receptor agonists (GLP-1 RAs) are synthetic peptides designed to mimic GLP-1 but resist DPP-4 degradation. They activate the GLP-1 receptor on target tissues, producing the same downstream effects as native GLP-1 but with dramatically extended duration of action.

Key Mechanisms

1. Glucose-dependent insulin secretion: The beta cell response is proportional to glucose levels, minimizing hypoglycemia risk
2. Appetite suppression: Central GLP-1 receptor activation in the hypothalamus and area postrema reduces hunger and increases satiety
3. Slowed gastric emptying: Food remains in the stomach longer, blunting postprandial glucose excursions and contributing to reduced caloric intake
4. Reduced hepatic glucose output: Through glucagon suppression and direct hepatic effects

Half-Life Engineering Strategies

The central challenge in GLP-1 RA development has been extending the half-life from 2 minutes to hours, days, or even weeks. Several strategies have been employed:

Fatty Acid Conjugation (Acylation)

Attaching a fatty acid side chain to the peptide enables reversible binding to serum albumin. Since albumin has a half-life of approximately 19 days and is recycled by the neonatal Fc receptor (FcRn), the peptide-albumin complex is protected from renal filtration and enzymatic degradation.

• Semaglutide: Uses a C18 fatty diacid chain linked via a mini-PEG spacer, achieving a half-life of approximately 7 days (once-weekly dosing)
• Liraglutide: Uses a C16 fatty acid (palmitic acid), achieving a half-life of approximately 13 hours (once-daily dosing)

DPP-4 Resistance Mutations

Modifying the amino acid at position 2 (the DPP-4 cleavage site) prevents enzymatic inactivation. For example, semaglutide incorporates an alpha-aminoisobutyric acid (Aib) substitution at position 2.

Amino Acid Substitutions for Stability

Strategic substitutions at other positions can reduce chemical degradation pathways:

• Replacing asparagine or glutamine residues to prevent deamidation
• Replacing methionine residues to prevent oxidation
• Introducing non-natural amino acids for protease resistance

The Evolution: Single to Dual to Triple Agonists

First Generation: Single GLP-1 Agonists

The first GLP-1 RAs activated only the GLP-1 receptor. They demonstrated clear efficacy in glycemic control and produced modest weight loss, establishing the class as a cornerstone of metabolic research.

Second Generation: Dual GLP-1/GIP Agonists

Tirzepatide was developed as a dual agonist that activates both GLP-1 and GIP receptors from a single molecule. The rationale was that combining two complementary incretin signals would produce additive or synergistic effects on insulin secretion, appetite, and body weight.

Clinical data confirmed this hypothesis: tirzepatide demonstrated greater weight reduction and glycemic improvement compared to selective GLP-1 RAs in head-to-head studies, with comparable or improved tolerability.

Third Generation: Triple GLP-1/GIP/Glucagon Agonists

Retatrutide represents the next evolution, activating three receptors simultaneously: GLP-1, GIP, and glucagon. The addition of glucagon receptor agonism is expected to:

• Further increase energy expenditure through thermogenesis
• Enhance hepatic lipid oxidation (relevant to fatty liver disease)
• Provide additional appetite suppression
• Improve lipid profiles through increased lipolysis

Early clinical data suggest that triple agonism may produce even greater weight reduction than dual agonism.

Comparison of Major GLP-1-Based Peptides

Property	Semaglutide	Tirzepatide	Retatrutide
Receptor Targets	GLP-1	GLP-1 + GIP	GLP-1 + GIP + Glucagon
Classification	Single agonist	Dual agonist	Triple agonist
Half-Life	~7 days	~5 days	~6 days
Dosing Frequency	Once weekly	Once weekly	Once weekly
Key Modification	C18 fatty diacid + Aib2	C20 fatty diacid	Fatty acid conjugation
Backbone	GLP-1 based	GIP based	GIP/glucagon hybrid
Weight Reduction	Significant	Greater than semaglutide	Potentially greatest
GI Tolerability	Nausea common (dose-dependent)	Potentially improved via GIP	Under investigation

Future Directions in Incretin Research

The field of incretin-based peptide research continues to evolve rapidly:

• Oral formulations: Semaglutide was the first GLP-1 RA available in oral form, using a permeation enhancer (SNAC) to enable gastrointestinal absorption. Research into oral delivery of other peptides in this class is ongoing.
• Combination with other targets: Amylin co-agonism, FGF21 integration, and other novel combinations are in preclinical development.
• Non-metabolic applications: GLP-1 RAs are being investigated for neurodegenerative diseases, cardiovascular protection, kidney disease, and addiction, expanding the research applications far beyond glucose metabolism.
• Small molecule GLP-1 agonists: Non-peptide oral GLP-1 receptor agonists are in development, which could expand access and simplify dosing.

Summary

The GLP-1 receptor agonist class represents one of the most significant advances in metabolic peptide research. From the discovery of the incretin effect to the engineering of long-acting single, dual, and triple agonists, each generation has built upon foundational biology to create increasingly powerful research tools. Understanding the underlying receptor pharmacology, half-life engineering strategies, and the rationale for multi-agonism provides essential context for researchers working with semaglutide, tirzepatide, retatrutide, and the next generation of incretin-based peptides.